Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Neurocrine Biosciences shares down on study
Yahoo/AP
Tuesday, September 10, 2013 - 10:22am
tags:
Neurocrine Biosciences, tardive dyskinesia
J&J Sues Boehringer Ingelheim Over Arbitration Dispute
Bloomberg
Tuesday, September 10, 2013 - 10:21am
tags:
JNJ, Boehringer Ingelheim
Depomed Expands Geographic Scope of License Agreement with Merck for Extended Release Metformin Patents
Yahoo
Monday, September 9, 2013 - 6:08pm
tags:
Depomed, Merck, metformin, patents
Dendreon: Crushed By JNJ/Medivation Or By Own Management?
Seeking Alpha
Monday, September 9, 2013 - 5:19pm
tags:
JNJ, Medivation, Dendreon, Provenge, Xtandi, Zytiga, prostate cancer
XenoPort to continue development of XP23829 after Phase 1 results
Yahoo/Fly on the Wall
Monday, September 9, 2013 - 5:18pm
tags:
XenoPort, XP23829, psoriasis, multiple sclerosis
Glaxo slips, Mylan gains after FDA guides on generic Advair
The Fly on the Wall
Monday, September 9, 2013 - 5:16pm
tags:
GSK, Mylan, FDA, generics, Advair
[video]What Are the Main Threats to AbbVie's Humira?
Motley Fool
Monday, September 9, 2013 - 5:15pm
tags:
AbbVie, Humira, Pfizer, Xeljanz
Valeant Pharmaceuticals Seeks to Cut Rates on $2.3 Billion Loans
Bloomberg/Businessweek
Monday, September 9, 2013 - 11:48am
tags:
loans, Valeant Pharmaceuticals
J&J Watchdog Employee Can Proceed With Retaliation Lawsuit
Pharmalot
Monday, September 9, 2013 - 11:16am
tags:
JNJ, whistleblower lawsuits
Why Neuralstem Represents An Enormous Opportunity For Investors
Seeking Alpha
Monday, September 9, 2013 - 11:15am
tags:
Neuralstem, StemCells, stem cells, NeoStem, NSI-566
Oncolytics lung cancer drug shrinks tumors in 92 percent of patients in trial
Reuters
Monday, September 9, 2013 - 10:47am
tags:
lung cancer, Oncolytics, Reolysin
Amarin Announces 30th Patent for Vascepa(R)
Yahoo
Monday, September 9, 2013 - 10:41am
tags:
Amarin, Vascepa, patents
Pharma Blasts EMA Draft Policy On Disclosing Clinical Trial Data
Pharmalot
Monday, September 9, 2013 - 10:40am
tags:
clinical trial data, clinical trials, EMA
Baxter and Gambro seal the deal on $3.9B acquisition
Mass Device
Monday, September 9, 2013 - 10:39am
tags:
Baxter International, Gambro, M&A, devices
Bayer's Xarelto faces stepped-up reports of side effects, deaths
Fierce Pharma
Monday, September 9, 2013 - 10:26am
tags:
Bayer, Xarelto, bloodthinners
Boehringer targets sales reps in new round of French job cuts
Fierce Pharma
Monday, September 9, 2013 - 10:25am
tags:
Boehringer Ingelheim, layoffs, France
Vivus' Qsymia Scripts Remain Flat
Seeking Alpha
Monday, September 9, 2013 - 9:55am
tags:
obesity, Arena Pharmaceuticals, Belviq, Eisai, Vivus, Qsymia, Anthony Zook
Assessing Arena's Belviq Sales After 3 Months
Seeking Alpha
Monday, September 9, 2013 - 9:54am
tags:
obesity, Arena Pharmaceuticals, Belviq, Eisai, Vivus, Qsymia
PDL BioPharma says 3Q revenue climbed 14 percent
Yahoo/AP
Monday, September 9, 2013 - 9:53am
tags:
earnings, PDL Biopharma
Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)
Yahoo
Monday, September 9, 2013 - 9:52am
tags:
Biodel, BIOD-123, clinical trials, diabetes, type 1 diabetes

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.